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Aim. Mechanisms of induction of apoptosis signaling pathways in mammalian tumor cells treated by novel hetero-
cyclic 4-thiazolidones with different side groups were studied. Methods. Annexin V/propidium iodide and DAPI
(4',6-diamidino-2-phenylindole) staining of cells, Western-blot analysis of specific proteins. Results. 4-Thiazo-
lidone derivatives of various structure possess similar cytotoxic activity in vitro (²Ñ
50
= 5 µM), and induce apop-
tosis in both leukemia (Jurkat, CCRF-CEM) and carcinoma (MCF-7, MDA-MD-231) cells. Western-blot ana-
lysis of the expression of several proteins of apoptosis signaling showed that the structure of lateral groups of 4-
thiazolidones may directly affect biological activity of these proteins in leukemia cells. In particular, com-
pounds Les-3120 (pyrazoline-substituted thiazolidinone) and Les-3166 (thiazolidinone-benzothiazole conjuga-
te) induced receptor-mediated apoptosis in Jurkat T-leukemia cells. 4-Iminothiazolidinone Les-3372 caused mi-
tochondrial type apoptosis, mediated by AIF protein. Conclusions. Structure-functional relationships between
the presence of specific side groups in novel 4-thiazolidones and the signaling apoptotic pathways induced by
these compounds have been established. The obtained results allow designing new, «hybrid» compounds which
can simultaneously induce more than one apoptotic pathway in tumor cells.
Keywords: tumor cells, apoptosis, 4-thiazolidones, caspases, AIF, structure-functional relationships.
Introduction. Recently, 4-thiazolidones and related
heterocyclic compounds have been demonstrated to be
a perspective source of innovative anticancer agents
[1–7]. These compounds are known for their broad bio-
logical activity, including antimicrobial, fungicidal,
antiviral, and antiinflammatory [5, 7]. Novel phar-
macological effects of 4-thiazolidones have been also
found, such as antidiabetic and anticancer. This has
resulted in the introduction of principally new group
of antidiabetic medicines into clinical practice, while
potential antitumor effects of 4-thiazolidones are still
under investigation [4, 6, 8].
The previous studies on antitumor activity of 4-thia-
zolidinone derivatives conducted at the Department of
Pharmaceutical, Organic and Bioorganic Chemistry of
Danylo Halytsky Lviv NationalMedical University allow-
ed identifying highly active compounds among the 4-
iminothiazolidinones (Les-3372), pyrazoline-substitu-
ted thiazolidinones (Les-3120) and thiazolidinone-ben-
zothiazole conjugates (Les-3166) (Fig. 1). Molecular mo-
deling of these compounds in silico revealed their incre-
ased affinity towards antiapoptotic proteins of the Bcl-2
family which are often overexpressed in leukemia and
lymphoma cells. Thus, Les-3166 and Les-3120 were
tested at the National Cancer Institute (USA) on a panel
of 60 tumor cell lines, and their high toxicity towards
myeloid cancer cells were revealed. That allowed us to
suggest a targeted action of Les-3120, Les-3166 and
Les-3372 towards leukemia cells, although the molecu-
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lar mechanisms of anticancer activity of these compo-
unds have not been tested yet. The main aim of this
work was to study signaling apoptotic pathways in va-
rious tumor cell lines under the action of selected 4-
thiazolidones, and to establish interrelationships bet-
ween the structure of thiazolidones molecule and the
mechanisms of cell death induced in tumor cells.
Materials and methods. Compounds Les-3120, Les-
3166 and Les-3372 were synthesized at the Department
of Pharmaceutical, Organic and Bioorganic Chemistry
(Danylo Halytsky Lviv National Medical University).
Doxorubicin was bought at the local pharmacy and pro-
duced by «Ebeve» (Austria).
Human T-leukemia cells of Jurkat and CCRF-CEM
lines were obtained from cell culture collection of R. E.
Kavetsky Institute of Experimental Pathology, Oncolo-
gy and Radiobiology, National Academy of Sciences of
Ukraine, human breast adenocarcinoma cells of MCF-7
and MDA-MD-231 lines were obtained from Ludwig
Institute for Cancer Research (Sweden). Cells were
cultured in the RPMI medium supplemented with 10 %
fetal calf serum («Sigma Chemical Co.», USA), 50 µg/
ml streptomycin («Sigma Chemical Co.»), 50 units/ml
penicillin («Sigma Chemical Co.») in 5 % CO2-contai-
ning humidified atmosphere at 37 oC.
For experiments, cells were seeded into 24-well tis-
sue culture plates («Greiner Bio-one», Germany). 2 mM
stock solutions of each 4-thiazolidone in DMSO (99.5%
pure, «Sigma», USA) were prepared, and additionally
dissolved in serum-free culture medium (RPMI for leu-
kemia cells and DMEM for carcinoma cells) prior to
addition to the cell culture. Final concentration of DMSO
in the cell culture was 0.5 % or less. Cytotoxicity stu-
dies on the Jurkat and MCF-7 cells revealed no stati-
stically significant toxicity of 0.5%DMSO solution to-
wards these cell lines.
Cytotoxic effect of antitumor drugs was studied
using the inverted microscope («Biolam-P1», «LOMO»,
RF) after cell staining with trypan blue dye (0.1 %).
FITC-conjugated Annexin V («BD Pharmingen»,
USA) and propidum iodide («Sigma») double staining
was performed to detect early apoptotic events under
treatment of Jurkat cels by 4-thiazolidones. In 3, 6, 12,
24 h after the addition of Les-3120, -3166, -3372, the
Jurkat cells were centrifuged at 2,000 rpm, washed twi-
ce with 1PBS, and incubated for 15min in Annexin V
binding buffer («BD Pharmingen») containing 1/20 vo-
lume of FITC-conjugated Annexin V solution and PI
(20 µg/ml). 10 µl of cell suspension were added to sli-
des and cover glasses were placed. Cytomorphological
investigations were performed with Zeiss AxioImager
A1 fluorescent microscope («Zeiss», Germany).
DAPI (4',6-diamidino-2-phenylindole) («Sigma»)
staining was performed for studying chromatin conden-
sation in MCF-7 cells at various time points of the Les-
3120, -3166, -3372 treatment. In 3, 6, 12, and 24 h after
the addition of 4-thiazolidones, the MCF-7 cells were
washed twice with 1 PBS, fixed in 4 % solution of
paraformaldehyde for 15 min at room temperature, and
then permeabilized by 0.1 % Triton X-100 solution in
PBS for 3 min. After that, the cells were incubated with
1 µg/ml solution of DAPI for 5 min, washed twice with
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Fig. 1. Structural formulas of stu-
died 4-thiazolidone derivatives
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PBS and cover glasses with fixed cells were placed on
slides. Cytomorphological investigations were perfor-
medwith Zeiss AxioImagerA1 fluorescentmicroscope.
Western blot analysis was used to evaluate the ex-
pression of proteins involved in signaling pathways of
apoptosis induced by 4-thiazolidones. After harvesting,
cell pellets were incubated with 50 µl of lysis buffer
(20 mM Tris-HCl, pH 7.5, 150 mMNaCl, 0.5 % Triton
X-100, 1 % Trasylol, 1 mM PMSF) per 106 cells, vorte-
xed, and centrifuged. Protein concentration in the super-
natants was measured, as described [9]. Then 1/5 vo-
lume of 5 Laemmli buffer (10 % SDS, 10 % 2-mer-
captoethanol, 40 % glycerol, 0.01 % bromphenol blue,
250 ìÌ Tris-HCl, pH 6.8) was added, and samples
were heated for 5 min in boiling water, and subjected to
Western-blot analysis. 50 µg of protein of each cell samp-
le was loaded onto 12 % polyacrylamide gel. After
electrophoresis (4 h at 0.02 A), proteins were trans-
ferred onto the nitrocellulose membrane («Amersham
Pharmacia Biotech», USA) for 1.5 h at 90 V usingMini
Trans-Blot Cell («BioRad», Sweden). Incubation of
membrane in 5 % milk solution for 1 h at 37 °C was
used to block nonspecific binding sites. Themembrane
was incubated with monoclonal rabbit antibodies rai-
sed against cleaved caspase-3, cleaved caspase-6, clea-
ved caspase-7, proteins Bid («Cell Signaling», USA),
AIF (sc-5586), Bax (sc-6236), Bcl-2 (sc-492), Bcl-
XL/S (sc-634) («Santa Cruz Biotech», USA), caspase-
9 (BD 556585) («BD Pharmingen»), -actin («Sigma»),
monoclonal goat antibodies against procaspase-3 (sc-
1226) («Santa Cruz Biotech»), and monoclonal mouse
antibodies against caspase-2, caspase-8 («BD Pharmin-
gen»), caspase-10 («MBL», USA) for 12 h at 4 oC with
slow shaking. Dilution for primary antibodies equaled
1:1,000 in 5 % BSA, 0.1 % PBS-Tween, except for
antibodies against -actin (1:5,000), as recommended
by supplier. After incubation with primary antibody,
the membrane was washed three times for 5 min in 1
PBS with 0.1 % Tween 20, and then incubated in
1:5,000 dilution of secondary anti-rabbit IgG horsera-
dish peroxidase-linked antibody («Amersham Pharma-
cia Biotech») for 1 h at room temperature. The memb-
rane was washed 3 times for 5min with PBS-Tween 20,
and proteins that bound antibodies were vizualized by
membrane incubation for 1min in ECL buffer (1.25 mÌ
luminol («Sigma»), 2.72 mÌ cumaric acid («Sigma»)
and 0.01 % H2O2 in 0.1 Ì Òris-HCl, ðÍ 8.5), and ex-
hibition for 10–15 min with X-ray film («Fujifilm»,
Japan). Relative amount of protein in the electrophore-
tic bands was quantified by using Gel-Pro Image Analy-
sis software («Media Cybernetics», USA). Protein loa-
ding normalization was conducted for -actin level in
the same samples.
Results and discussion. At the first stage of this
work, the anticancer activity and effective inhibiting con-
centration of 4-thiazolidones were evaluated. For this,
LC50 index was used, calculated as a lethal concentra-
tion of drug, which kills 50 % cells in comparison with
a control culture. In Fig. 2, A, B, the cytotoxic activity
of Les-3120, Les-3166 and Les-3372 towards the hu-
man T-leukemia cells of Jurkat and CCRF-CEM lines
are shown.
It was found that all compounds under study inhibi-
ted proliferation of leukemia cells in dose-dependent
mode in 24 h after their addition to the culture medium.
Jurkat cells appeared to be more sensitive towards Les-
3120, -3166 and -3372, compared to other leukemia cells
of ÑÑRF-CEM line. For studying specificity of antican-
cer activity of 4-thiazolidones, their cytotoxic effect
was analyzed using another in vitro model – breast ade-
nocarcinoma cells of MCF-7 and MDA-MD-231 lines.
It was revealed that the cells of high-invasive breast
adenocarcinoma of MDA-MD-231 line were among
the most sensitive to the action of 4-thiazolidones, sin-
ce LC50 of all tested compounds equaled 1 µM (Fig. 2,
C, D). However, other carcinoma cells of MCF-7 line
were 10 times more resistant to thiazolidones action
compared to MDA-MD-231 line. Thus, the cytotoxic
activity of these compounds seems to depend on the spe-
cificity of each cell line tested. It should be noted, that
all three studied compounds (Les-3120, Les-3166 and
Les-3372), despite substantial differences in their che-
mical structure, demonstrated similar indexes of their
cytotoxic activity towards tumor cells (Fig. 2). Average
LC50 index was very close for all three compounds –
5 µM, however, it was still 10 times higher, than that of
the doxorubicin (0.5 µM) – anticancer drug which is al-
ready used in clinics.
Three main cell death mechanisms have been iden-
tified – apoptosis, autophagy, and necrosis [10]. Cell nec-
rosis is undesirable phenomenon during chemotherapy
treatment, since it results in development of massive in-
flammatory processes in the organism of cancer patients,
which can significantly complicate a treatment process.
In contrast, the induction of apoptosis by anticancer
drugs leads to quick phagocytosis of remnants of tumor
cells by the macrophages that considerably diminish the
development of side effects of chemotherapy.
Cytomorphologic studies were performed to identify
in which way – apoptotic or necrotic – 4-thiazolidones
induce death of target cells. Phosphatidylserine trans-
location to the external layer of the cell membrane of dy-
ing cells measured by the Annexin V test is considered
to be one of the earliest hallmarks of apoptosis [11]. Pro-
pidium iodide is a DNA targeting dye which detects
only necrotic cells, since alive cells use membrane pumps
to move it outside into the extracellular medium. Sup-
ravital double staining of the Jurkat T-leukemia cells,
treated with Les-3120, -3166, -3372 (5 µM), with FITC-
conjugated annexin V and propidium iodide revealed
that all tested compounds induced apoptosis in leuke-
mia cells (Fig. 3, see inset). Doxorubicin in comparable
concentration (4 µM) led to the secondary necrosis.
Chromatin condensation is another important cha-
racteristic of apoptosis. It can be easily measured by
using the DNA-intercalating dyes, such as DAPI. We
have revealed that all three compounds (10 µM) cause
the development of chromatin hyper-condensation in
MCF-7 cells, and also induced apoptosis in carcinoma
cells (Fig. 4, see inset). Thus, structurally different
members of 4-thiazolidones possessed similar cytoto-
xic activity and induced apoptosis in both leukemia and
carcinoma cells.
Molecular mechanisms of apoptosis induced by an-
ticancer drugs are divided into two main pathways: de-
ath receptor (DR)-dependent and DR-independent (mi-
tochondrial) [12]. Extrinsic (receptor-mediated) path-
way starts with binding the death receptor (e. g. Fas) by
a cognate ligand (e. g. FasL), which causes the recruit-
ment of adaptor proteins (e. g. TRADD and FADD)
and initiator procaspase-8 molecules to the cytosolic
side of the receptor to form the death-inducing signa-
ling complex (DISC) [13, 14]. Inmost cell types (type I),
active caspase-8 activates the executioner caspase-3,
which, in turn, is responsible for many of morphological
and biochemical manifestations of apoptosis. In other
cell types (type II) the amount of caspase-8 activated
within DISC is low and insufficient for direct activation
of downstream executioner procaspases, including cas-
pase-3 and -7 [16]. Instead, active caspase-8 in type II
cells is known to cleave the cytosolic BH3-only protein
Bid to truncated Bid (tBid) [15]. In turn, tBid can ac-
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Fig. 2. Cytotoxic effect of Les-3120 (1), Les-3166 (2) and Les-3372 (3) on human T-leukemia cells of Jurkat (À) and CCRF-CEM (B) lines and
human breast adenocarcinoma cells of MDA-MD-231 (C) and MCF-7 (D) lines after 24 h of incubation
tivate the multidomain Bcl-2 family protein (i. e. Bax
and Bak) that stimulates the mitochondrial outer memb-
rane permeabilization (MOMP) and the release of inter-
membrane space proteins into cytosol [17].
A critical event in the initiation of DR-independent
apoptosis is mitochondrial dysfunction, which is regu-
lated by the Bcl-2 family proteins [12]. After induction
of the apoptotic stimuli by anticancer drugs, the pro-
apoptotic proteins, including Bax, Bak and Bad, are in-
duced in accordance with their sensitivity to the anti-
cancer drugs. The homodimerized Bax acts on VDAC,
localized in the outer membrane of mitochondria, resul-
ting in the release of cytochrome c which activates the
caspase cascade [18]. In particular, oligomerization of
a cytochrome c/Apaf-1/procaspase-9 complex (apopto-
some) leads to caspase-9 activation causing the clea-
vage of downstream effector caspase-3 and -7 in the pre-
sence of dATP leading to apoptosis [19].
For identification of apoptotic signaling pathways,
induced by Les-3120, Les-3166 and Les-3372 in trea-
ted tumor cells, Western-blot analysis was performed
using 15 antibodies against proteins involved in early
and late stages of apoptosis. The sequence of action of
initiator and effector caspases, activated under the in-
fluence of these compounds, was studied in time-de-
pendent mode at several time checkpoints (3, 6, 12, 24 h)
after drug addition to the culture medium. The Jurkat T-
leukemia cells, which are known to be among the most
sensitive to thiazolidones action, were used as an experi-
mental model line in these studies. Equal protein loa-
ding onto the gel and at Western blotting was assessed
after the incubation of membranes with antibodies aga-
inst -actin.
In Fig. 5, the expression of effector and initiator apo-
ptotic enzymes under the action of Les-3120, -3166,
and -3372 in the Jurkat T-cells is shown. Doxorubicin
(4 µM) was used as a positive control. It was revealed
that the usage of compounds with different structure of
side groups led to various activation of effector cas-
pases. An impact of Les-3120 and Les-3166 did that
already in 12 h after starting treatment, while Les-
3372 possessing the same IC50 (5 µM), caused the activa-
tion of caspase-3, -7 and subsequent cleavage of PARP-
1 and DFF45 only in 24 h. This phenomenon can be ex-
plained by different mechanisms of the action of these
compounds. To confirm this hypothesis, the expressi-
on of the initiator caspases and small mitochondrial pro-
teins was analysed.
Les-3120 and Les-3166 also activated caspase-8 in-
volved in the receptor-mediated apoptosis and subse-
quent cleavage of Bid protein by caspase-8 in 12 h, whi-
le Les-3372 did not possess such activities (Fig. 5). Ano-
ther initiator caspase-10, also involved in receptor-me-
diated apoptosis, was partially cleaved by Les-3120 and
Les-3166, but not by Les-3372, in 24 h. The Bid pro-
tein is known to be a «bridge» between the cell death re-
ceptors and mitochondria, effectively transmitting a sig-
nal from the Fas/CD95 receptor to these organelles. Les-
3372 had no effect on the expression of this protein.
Significant cleavage of procaspase-9, involved in
the mitochondrial-type apoptosis, was found only in the
cells treated with Doxorubicin (positive control) and
Les-3372 (at 24 h), while other compounds (Les-3120
and Les-3372) had weak effect on the expression of this
initiator caspase. No statistically significant differen-
ces in the expression of proapoptotic mitochondrial Bax
protein and antiapoptotic Bcl-xL protein were obser-
ved under the action of 4-thiazolidones, while the amo-
unt of another mitochondrial protein – AIF (apoptosis-
inducing factor) – involved in the caspase-independent
apoptosis [20], was increased already in 12 h in Les-
3372-treated cells.
No changes were found in the expression of procas-
pase-2 (involved in the intrinsic, endoplasmic reticu-
lum(ER)-mediated apoptosis) [21] under the treatment
of Les-3120 and Les-3166, while Les-3372 and Doxo-
rubicin did cleave those proteases. Thus, it is probable
that the ER is not important in the Les-3120 and Les-
3166-induced apoptosis, while in case of Les-3372 both
ER and mitochondria could be of high importance.
Summarizing, Les-3120 leads to the activation of
procaspase-8 and to subsequent cleavage by this caspa-
se its substrate – Bid, in 12 h after the treatment of the
Jurkat T-cells. This process is accompanied by the acti-
vation of effector caspases-3, -7, and cleavage of DNA-
reparation enzymes PARP-1 and DFF45 by these cas-
pases. Only weak signs of the caspase-9 activation (in-
volved in the mitochondria-induced apoptosis) were
found. Taking into consideration that the Jurkat cells
belong to type II, where the mitochondria activation is
required for successful induction of the DR-dependent
apoptosis [15], we suggest that Les-3120 leads to recep-
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tor-induced, but mitochondria-mediated apoptosis that
is arbitrated by caspase-8 and effector caspases-3, -7.
Les-3166 also causes early activation of caspase-8
and Bid in 12 h after starting treatment. The Bid clea-
vage and weak activation of caspase-9 indicate the pos-
sible involvement of mitochondria in Les-3166-indu-
ced apoptosis. That leads to the activation of the effec-
tor caspases-3, -7 by the apoptosome complex, and clea-
vage of DFF45 and PARP-1 by these caspases. Thus,
Les-3166 seems to cause receptor-induced, mitochond-
ria-mediated apoptosis, like Les-3120.
Les-3372, despite the IC50 index, similar to Les-3120
and Les-3166, leads to a weak caspase-7 activation and
a weak cleavage of PARP-1 and DFF45 in the Jurkat
T-cells only in 24 h after the addition of drug to the cul-
ture medium. A decrease in the level of procaspase-2
(mediator of intrinsic, ER-induced apoptosis) and ap-
pearance of cleaved form of caspase-9 (a mediator of the
mitochondria-induced apoptosis) were found in 24 h af-
ter Les-3372 treatment. However, a significant increase
in the AIF level in 12 h was the earliest event observed
in the case of Les-3372 action (Fig. 5). AIF is known to
induce the mitochondria-mediated caspase-indepen-
dent apoptosis. Thus, Les-3372 leads to the activation
of intrinsic apoptotic pathways, mediated bymitochond-
ria, and caspases seem to play a minor role here.
A scheme of signaling apoptotic pathways induced
in tumor cells by different 4-thiazolidone derivatives is
shown in Fig. 6.
Conclusions. We suggest that the structure of side
groups of novel heterocyclic 4-thiazolidone derivatives
can affect not only the anticancer activity of these deri-
vatives, but also the activation of specific signaling apop-
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Fig. 6. General scheme of signaling apoptotic pathways, induced by stu-
died 4-thiazolidone derivatives in tumor cells
totic pathways induced by these compounds in tumor
cells. Les-3120 and Les-3166 seem to cause the recep-
tor-induced but mitochondria-mediated apoptosis, and
Les-3372 may be involved in the caspase-independent,
AIF-mediated apoptosis. The data obtained suggest de-
finite relationships between chemical structure of side
groups of 4-thiazolidones and molecular mechanisms
of their anticancer activity. These data should be of gre-
at value at designing novel, «hybrid» thiazolidones com-
bining in their structure lateral groups of different com-
pounds and, thus, being more active comparing to their
predecessor «parental» compounds.
Acknowledgements. This work was partially sup-
ported by personal grants of theWest-Ukrainian Biome-
dical Research Center (WUBMRC) to R. Panchuk, V.
Chumak and D. Havrylyuk in 2010–2012, and Grant of
the President of Ukraine #F32-192/2011 to R. Panchuk.
Ð. Ð. Ïàí÷óê, Â. Â. ×óìàê, Ì. Ð. Ô³ëü, Ä. ß. Ãàâðèëþê,
Á. Ñ. Ç³ìåíêîâñüêèé, Ð. Á. Ëåñèê, Ð. Ñ. Ñòîéêà
Äîñë³äæåííÿ ìîëåêóëÿðíèõ ìåõàí³çì³â ïðîàïîïòè÷íî¿ ä³¿
íîâèõ ãåòåðîöèêë³÷íèõ ïîõ³äíèõ 4-ò³àçîë³äîí³â
Ðåçþìå
Ìåòà. Äîñë³äèòè ìåõàí³çìè ³íäóêö³¿ àïîïòè÷íèõ ñèãíàëüíèõ øëÿ-
õ³â íîâèìè ãåòåðîöèêë³÷íèìè ïîõ³äíèìè 4-ò³àçîë³äîí³â ç³ ñòðóê-
òóðíî â³äì³ííèìè á³÷íèìè ãðóïàìè ó çëîÿê³ñíèõ êë³òèíàõ ññàâö³â.
Ìåòîäè. Ôàðáóâàííÿ êë³òèí àííåêñèíîì V, éîäèäîì ïðîï³ä³þ,
DAPI, Âåñòåðí-áëîò àíàë³ç. Ðåçóëüòàòè. Ñòðóêòóðíî â³äì³ííèì
ïîõ³äíèì 4-ò³àçîë³äîí³â ïðèòàìàííà ñõîæà öèòîòîêñè÷íà àê-
òèâí³ñòü (²Ñ50 = 5 ìêÌ), âîíè òàêîæ ³íäóêóþòü àïîïòîç ó ëåéêîç-
íèõ (Jurkat, CCRF-CEM) ³ êàðöèíîìíèõ (MCF-7, MDA-MD-231) êë³-
òèíàõ. Âåñòåðí-áëîò àíàë³çîì ³ç âèêîðèñòàííÿì íèçêè àíòèò³ë äî
á³ëê³â, ôóíêö³îíóþ÷èõ íà ð³çíèõ ñòàä³ÿõ àïîïòîçó, ïîêàçàíî, ùî
ñòðóêòóðà á³÷íèõ ãðóï 4-ò³àçîë³äîí³â ìîæå áåçïîñåðåäíüî âïëèâà-
òè íà á³îëîã³÷íó àêòèâí³ñòü öèõ àïîïòè÷íèõ á³ëê³â ó ëåéêîçíèõ êë³-
òèíàõ-ì³øåíÿõ. Çîêðåìà, ñïîëóêè Les-3120 (ï³ðàçîë³í-çàì³ùåíèé
ò³àçîë³äèíîí) òà Les-3166 (êîí’þãàò ò³àçîë³äèíîíó ³ áåíçò³àçîëó)
³íäóêóþòü ðåöåïòîð-îïîñåðåäêîâàíèé àïîïòîç ó êë³òèíàõ Ò-ëåéêå-
ì³¿ ëþäèíè ë³í³¿ Jurkat. 4-²ì³íîò³àçîë³äèíîí Les-3372 çóìîâëþº àïîï-
òîç ì³òîõîíäð³àëüíîãî òèïó, îïîñåðåäêîâàíèé á³ëêîì AIF. Âèñíîâ-
êè. Âñòàíîâëåíî ñòðóêòóðíî-ôóíêö³îíàëüí³ âçàºìîçâ’ÿçêè ì³æ
ñïåöèô³÷íèìè á³÷íèìè ãðóïàìè ó ìîëåêóëàõ 4-ò³àçîë³äîí³â òà ñèã-
íàëüíèìè øëÿõàìè àïîïòîçó, ùî äîçâîëÿº êîíñòðóþâàòè íîâ³,
«ã³áðèäí³» ïðåïàðàòè ç ïîòåíö³éíîþ çäàòí³ñòþ îäíî÷àñíî çà-
ïóñêàòè ê³ëüêà àïîïòè÷íèõ êàñêàä³â ó êë³òèíàõ-ì³øåíÿõ.
Êëþ÷îâ³ ñëîâà: ïóõëèíí³ êë³òèíè, àïîïòîç, 4-ò³àçîë³äîíè, êàñ-
ïàçè, AIF, ñòðóêòóðíî-ôóíêö³îíàëüí³ âçàºìîçâ'ÿçêè.
Ð. Ð. Ïàí÷óê, Â. Â. ×óìàê, Ì. Ð. Ôèëü, Ä. ß. Ãàâðèëþê,
Á. Ñ. Çèìåíêîâñêèé, Ð. Á. Ëåñèê, Ð. Ñ. Ñòîéêà
Èññëåäîâàíèå ìîëåêóëÿðíûõ ìåõàíèçìîâ ïðîàïîïòè÷åñêîãî
äåéñòâèÿ íîâûõ ãåòåðîöèêëè÷åñêèõ ïðîèçâîäíûõ 4-òèàçîëèäîíîâ
Ðåçþìå
Öåëü. Èññëåäîâàòü ìåõàíèçìû èíäóêöèè àïîïòè÷åñêèõ ñèãíàëü-
íûõ ïóòåé íîâûìè ãåòåðîöèêëè÷åñêèìè ïðîèçâîäíûìè 4-òèàçî-
ëèäîíîâ ñî ñòðóêòóðíî îòëè÷àþùèìèñÿ áîêîâûìè ãðóïïàìè â
çëîêà÷åñòâåííûõ êëåòêàõ ìëåêîïèòàþùèõ. Ìåòîäû. Îêðàøèâà-
íèå êëåòîê àííåêñèíîì V, èîäèäîì ïðîïèäèÿ, DAPI, Âåñòåðí-áëîò
àíàëèç. Ðåçóëüòàòû. Ñòðóêòóðíî ðàçëè÷àþùèåñÿ ïðîèçâîäíûå 4-
òèàçîëèäîíîâ îáëàäàþò ñõîæåé öèòîòîêñè÷åñêîé àêòèâíî-
ñòüþ (²Ñ50 = 5 ìêÌ) è èíäóöèðóþò àïîïòîç â ëåéêîçíûõ (Jurkat,
CCRF-CEM) è êàðöèíîìíûõ (MCF-7, MDA-MD-231) êëåòêàõ. Âåñ-
òåðí-áëîò àíàëèçîì ñ èñïîëüçîâàíèåì ðÿäà àíòèòåë ê áåëêàì,
ôóíêöèîíèðóþùèì íà ðàçíûõ ñòàäèÿõ àïîïòîçà, ïîêàçàíî, ÷òî
ñòðóêòóðà áîêîâûõ ãðóïï 4-òèàçîëèäîíîâ ìîæåò íåïîñðåäñòâåí-
íî âëèÿòü íà áèîëîãè÷åñêóþ àêòèâíîñòü ýòèõ ïðîàïîïòè÷åñêèõ
áåëêîâ â ëåéêîçíûõ êëåòêàõ-ìèøåíÿõ. Â ÷àñòíîñòè, ñîåäèíåíèÿ
Les-3120 (ïèðàçîëèí-çàìåùåííûé òèàçîëèäèíîí) è Les-3166 (êîíú-
þãàò òèàçîëèäèíîíà è áåíçòèàçîëà) èíäóöèðóþò ðåöåïòîð-îïî-
ñðåäîâàííûé àïîïòîç â êëåòêàõ Ò-ëåéêåìèè ÷åëîâåêà ëèíèè Jur-
kat. 4-Èìèíîòèàçîëèäèíîí Les-3372 ïðåäîïðåäåëÿåò àïîïòîç ìè-
òîõîíäðèàëüíîãî òèïà, îïîñðåäîâàííûé áåëêîì AIF. Âûâîäû. Óñ-
òàíîâëåíû ñòðóêòóðíî-ôóíêöèîíàëüíûå âçàèìîñâÿçè ìåæäó ñïå-
öèôè÷åñêèìè áîêîâûìè ãðóïïàìè â ìîëåêóëàõ 4-òèàçîëèäîíîâ è
ñèãíàëüíûìè ïóòÿìè àïîïòîçà, ÷òî ïîçâîëÿåò êîíñòðóèðîâàòü
íîâûå, «ãèáðèäíûå» ïðåïàðàòû ñ ïîòåíöèàëüíîé ñïîñîáíîñòüþ
îäíîâðåìåííî çàïóñêàòü íåñêîëüêî àïîïòè÷åñêèõ êàñêàäîâ â êëåò-
êàõ-ìèøåíÿõ.
Êëþ÷åâûå ñëîâà: îïóõîëåâûå êëåòêè, àïîïòîç, 4-òèàçîëèäîíû,
êàñïàçû, AIF, ñòðóêòóðíî-ôóíêöèîíàëüíûå âçàèìîñâÿçè.
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Fig. 3. Proapoptotic activity of 4-
thiazolidone derivatives (Jurkat T-
leukemia cells, annexin V/PI stai-
ning, 24 h)
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Fig. 4. Cytomorphological studies
of chromatin structure of MCF-7
cells under treatment of 4-thiazo-
lidones. DAPI staining, 24 h
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